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Nuclear factor KB (NF-KB) is a critical regulator of several genes which are involved in immune and
inflammation responses. NF-KB, consisting of a 50-kDa protein (p50) and a 65-kDa protein (p65), is bound to a
cytoplasmic retention protein called IKB. Stimulation of cells with a variety of inducers, including cytokines such
as tumor necrosis factor and interleukin-1, leads to the activation and the translocation of p50/65 NFdKB into the
nucleus. However, the in vivo mechanism of the activation process remains unknown. Here, we provide the first
evidence that the in vivo mechanism of NF-KB activation is through the phosphorylation and subsequent loss of
its inhibitor, IKBkv. We also show that both IicBa loss and NF-KB activation are inhibited in the presence of
antioxidants, demonstrating that the loss of IKBea is a prerequisite for NF-KB activation. Finally, we demonstrate
that IKBa is rapidly resynthesized after loss, indicating that an autoregulatory mechanism is involved in the
regulation ofNF.KB function. We propose a mechanism for the activation of NF-KB through the modification and
loss of IKBa, thereby establishing its role as a mediator of NF.KB activation.
The transcription factor NF-KB has been identified as a
critical component of several signal transduction pathways.
Its widespread biological significance is demonstrated in part
by its activation in response to several different agents in a
variety of cell types (for a review of NF-KB, see references
5 and 22). Activation of NF-KB involves its release from a
cytoplasmic inhibitor protein, IKB, and subsequent translo-
cation of active NF-KB into the nucleus (3). Nuclear NF-KB
regulates a variety of genes involved in immune and inflam-
mation responses such as those encoding interleukin-2 (IL-
2), major histocompatibility complex class I, IL-6, and
cellular adhesion molecules (5, 22). Numerous agents which
can cause the release of NF-KB from IKB have been identi-
fied; they include inflammatory cytokines like tumor necro-
sis factor alpha (TNF-a) and IL-la; the tumor promoter and
activator of protein kinase C, phorbol myristate acetate
(PMA); bacterial lipopolysaccharides (LPS); DNA-damag-
ing agents; double-stranded RNA, and infection by viruses
including human immunodeficiency virus type 1 (5, 22).
Interestingly, recent studies have shown that antioxidants
can block the activation of NF-KB by various inducers (41,
42, 45), raising the intriguing possibility that the ability of
diverse signaling pathways to activate NF-KB could involve
the production of reactive oxygen intermediates (ROI).
TNF and IL-1 are multifunctional cytokines which medi-
ate various inflammation and cellular immune responses in
part by their abilities to regulate the expression of other
cytokine genes (for example, IL-6) (for a review, see refer-
ences 14 and 50). In many cases, the transcriptional regula-
tory properties of TNF and IL-1 are mediated by their
abilities to activate NF-KcB (16, 33, 37). Interestingly, it has
been shown that the TNF-a and IL-la activation of NF-KB
occurs independently of protein kinase C (10, 18). Recently,
it has been reported that TNF-a signaling involves a phos-
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pholipid pathway which leads to the production of ceramide
catalyzed by the enzyme sphingomyelinase (15, 43). It has
been proposed that 1,2-diacylglycerol (DAG) can lead to the
activation of both protein kinase C and sphingomyelinase
and that both of these enzymes can eventually lead to the
activation of NF-KB (43). These observations demonstrate
that distinct pathways can lead to the activation of NF-KB.
The in vivo mechanism of NF-KB activation is unknown,
although in vitro experiments have suggested that phosphor-
ylated IKB can no longer interact with NF-KB (20, 30, 44).
The best-characterized member of the NF-KB family (orig-
inally defined as NF-KB) consists of a 50-kDa protein (NF-
KB1), which is derived from a 105-kDa precursor, and a
65-kDa protein (RelA) (4, 11, 17, 21, 31). Dimerization
between NF-KB family members is mediated through the
highly conserved N-terminal region, which has been called
the rel homology region (21, 31, 35, 36, 39). The p65 subunit
also has a C-terminal transcriptional activation domain,
making p50/65 NF-KB a potent transcriptional activator (6,
40). Members of the NF-KB family are typically localized in
the cytoplasm through the masking of their nuclear localiza-
tion sequence by the associated IKB molecule (8, 9, 25).
Several forms of IKB, including IKBaIMAD-3 and its avian
homolog pp4O, Bcl-3, IKBdy, and the p105 precursor of the
p50 subunit of NF-KB, have now been described (13, 19, 23,
24, 27, 38). Purification and determination of peptide se-
quences of a major form of IKB, called IKBa (13), revealed
that they were identical to the predicted protein sequence of
the MAD-3 clone (23). We refer to this protein as IKBa/
MAD-3 in this article. All the IKB forms identified to date
contain multiple copies of the so-called ankyrin/SWI6 re-
peats, which have been shown to be involved in interactions
with NF-KB (28, 51). The presence of multiple forms of IKB
and NF-KB subunits underscores the role of this transcrip-
tion factor family in numerous cellular events and exempli-
fies the combinatorial complexity of their regulation.
The widespread biological importance of NF-KB has di-
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rected considerable attention towards understanding its
mechanism of activation. Here, we provide the first in vivo
evidence that stimulation of cells with a variety of NF-KB
inducers can lead to the phosphorylation and the rapid loss
of IKBot/MAD-3. The time course of IKBot/MAD-3 loss
correlates with the appearance of nuclear NF-KB. Interest-
ingly, two different forms of NF-KB associated with IKBoB/
MAD-3 were found, with one form being the typical p50/65
heterodimer and the other form likely being a p65 ho-
modimer. Stimulation of cells led to the release of both of
these NF-KB forms. Our data also demonstrate that IKBot/
MAD-3 is rapidly resynthesized after loss, thereby suggest-
ing an autoregulatory mechanism for NF-KB regulation.
MATERIALS AND METHODS
Cell culture and reagents. HeLa S3 cells were grown in
Dulbecco modified Eagle medium H supplemented with 10%
horse serum in a spinner flask. Jurkat T cells and 70Z/3 pre-B
cells were grown in RPMI 1640 plus 10% fetal calf serum.
TNF-ao was obtained from Promega and used at a concen-
tration of 10 ng/ml. PMA, phytohemagglutinin (PHA), and
LPS were obtained from Sigma and were used at concentra-
tions of 100 ng/ml, 1 ,ug/ml, and 10 [Lg/ml, respectively. IL-la
was obtained from Promega and was used at a concentra-
tion of 5 ng/ml. Pyrrolidinedithiocarbamate (PDTC) and
N-acetyl-L-cysteine (NAC) were both obtained from Sigma
and were used at concentrations of 100 ,uM and 30 mM,
respectively, for 30 or 60 min before stimulation of cells with
NF-KB inducers.
Antibodies. The IKBda/MAD-3 antibody (Ab 9) has been
previously described (8). The p65 N-terminal antibody (p65-
NAb) was generated by injecting rabbits with a peptide
containing amino acids 1 to 21 of the predicted human p65
amino acid sequence (39). The p65 C-terminal antibody
(p65-CAb) was a gift from W. Greene and was generated
against a peptide containing amino acids 528 to 550 of human
p65. The IKBotIMAD-3 C-terminal antibody (IKBoa/MAD-3-
CAb) and the c-Rel antibody 265 were gifts from N. Rice.
IKBoa/MAD-3-CAb was generated against the 17 C-terminal
amino acids of the human IKBa/MAD-3 clone (38), while the
c-Rel antibody was against amino acids 573 to 587 of human
c-Rel (12). The p50 Ab 2 was a gift from A. Israel and has
been previously described (31).
Immunoprecipitations. Coimmunoprecipitation of the two
deoxycholate (DOC)-activated NF-KB forms (Fig. 1A) with
IKBaIMAD-3-Ab 9 were carried out by the addition of either
2 ,ul of IKBoa/MAD-3-Ab 9 alone or 2 ,ul of IKBoa/MAD-3-Ab
9 plus 2 ,ug of the competing peptide to 20 ,ul of HeLa
cytoplasmic extract, followed by a 10-min incubation at
room temperature. The cytoplasmic extracts were then
added to 20 pl (1:1) of protein A-Sepharose (Sigma), incu-
bated for another 10 min with frequent mixing, then washed
twice with Tris-buffered saline, and finally resuspended in 20
,ul of Tris-buffered saline. DOC was then added to a final
concentration of 0.8% and incubated for another 5 min, after
which Nonidet P-40 (NP-40) was added to a final concentra-
tion of 1.2%. Two microliters of the resulting cytoplasmic
extract was then analyzed by a gel shift assay (Fig. 1A). In a
different experiment, 2 RI of Ab 2 against the p50 subunit of
NF-idB or preimmune serum was added to 20 ,ul of HeLa
cytoplasmic extract, and then protein A-Sepharose was
added as described above. The supernatant was then re-
moved and analyzed by a gel shift assay (Fig. 1B).
35S-labeled extracts were made by first growing 107 cells in
1 ml of medium without methionine and cysteine for 1 h,
then adding 35S-labeled methionine and cysteine (Translabel;
ICN) to a concentration of 0.5 mCi/ml, and incubating for
another 2 h in a 37°C incubator. The cells were then lysed in
1 ml of RIP buffer (25 mM Tris-HCl, 150 mM NaCl, 2 mM
EDTA, 0.5% NP-40, and a protease inhibitor cocktail) for 10
min on ice. The lysates were then spun in a microcentrifuge
for 10 min, after which the supernatants were removed. One
hundred microliters of the supernatant was then diluted with
200 pl of RIP buffer, and the appropriate immune serum
alone or immune serum plus peptide was added. The anti-
body binding reactions were allowed to proceed for 30 min
on a rotating wheel at 4°C, after which the lysates were
briefly spun, and the supernatant was added to 40 ,ul of
protein A-Sepharose (1:1) and incubated for another 60 min.
The lysate supernatants were then discarded, and the protein
A-Sepharose beads were washed twice in each of the follow-
ing buffers as previously described (47): (i) 1 M NaCl-20 mM
Tris-HCl (pH 7.6)-0.1% NP-40, (ii) 0.2 M NaCl-20 mM
Tris-HCl-1% NP-40-0.1% sodium dodecyl sulfate (SDS)-1
mM EDTA, and (iii) 20 mM Tris-HCl-0.1% NP-40. The
beads were then boiled for 5 min in an SDS-polyacrylamide
gel electrophoresis (SDS-PAGE) loading buffer and spun,
and the supernatants were loaded onto SDS-denaturing gels.
The gels were then analyzed by fluorography.
For phosphate labeling, 10 cells were grown in media
without phosphate for 3 h, and then [32P]H3P04 was added
to 1 mCi/ml for 15 min. The cells were then induced with
various agents for the periods indicated elsewhere in the
text. The immunoprecipitations were carried out as de-
scribed above except that phosphatase inhibitors (50 mM
NaF, 10 mM Na3VO4, and 50 mM ,B-glycerophosphate) were
also included in the RIP buffer. The immunoprecipitates
were then analyzed by SDS-PAGE followed by autoradiog-
raphy.
Nuclear and cytoplasmic extracts. Cells were fractionated
by a combination of two previously described procedures
(10, 46). Briefly, cells were washed in phosphate-buffered
saline, pelleted, and resuspended in lysis buffer (10 mM
Tris-HCl [pH 8.0], 60 mM KCl, 1 mM EDTA, 1 mM
dithiothreitol, protease inhibitors, and NP-40). NP-40 con-
centrations used were 0.3% for HeLa cells, 0.1% for 70Z/3
cells, and 0.075% for Jurkat cells. After 5 min on ice, the
lysates were spun at 2,500 rpm in a microcentrifuge at 4°C
for 4 min. The supernatant was then removed and respun at
14,000 rpm for 5 min. The supernatants were used as
cytoplasmic extracts. The pelleted nuclei from the first spin
were briefly washed in lysis buffer without NP-40. The
nuclear pellet was then resuspended in an equal-volume
nuclear extract buffer (20 mM Tris-HCl [pH 8.0], 420 mM
NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, and 25% glycerol),
and then 5 M NaCl was added to achieve a final salt
concentration of 400 mM. After a 10-min incubation at 4°C,
the nuclei were briefly vortexed and spun at 14,000 rpm for
5 min. The supernatant was then removed and used as a
nuclear extract.
Gel shift assays. Gel shift assays were carried out as
previously described (23). DOC reactions were performed
by the addition of sodium DOC to a concentration of 0.8%
for 5 min, after which NP-40 was added to a concentration of
1.2%. Radiolabeled probe and poly(dI-dC). (dI-dC) were
then added, and the binding reaction mixtures were incu-
bated for 15 min before being loaded onto nondenaturing gels.
Western blots. Western blots (immunoblots) were carried
out either with the Western blot AP system (Promega) or by
ECL Western blotting (Amersham) according to the manu-
facturer's recommendations. IKBid/MAD-3 was dephosphor-
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FIG. 1. Two forms of NF-KB are associated with IKBU/MAD-3. (A) A gel shift assay analyzing the NF-KB forms that are immunopre-
cipitated with an antibody against IKBaoMAD-3 (IKBa/MAD-3-Ab 9) using HeLa cytoplasmic extracts. Lanes 1 and 2, binding activity before
(-) and after (+) treatment with DOC, respectively; lanes 3 and 4, binding activity immunoprecipitated in the presence of IKBcx/MAD-3-Ab
9 alone or IKBa/MAD-3-Ab 9 plus the competing peptide (P), respectively. The two DOC-activated forms that bind to a major
histocompatibility complex class I enhancer probe are indicated (arrows). IP, immunoprecipitate. (B) A gel shift assay analyzing the effects
of various antibodies on the two forms of NF-KB. Lanes 1 and 2, extracts incubated with a p50 antibody (Ab 2) and protein A-Sepharose or
with preimmune (PI) serum and protein A-Sepharose, respectively. After the incubations, the extracts were treated with DOC and analyzed
by a gel shift assay. Lanes 3 and 4, effect of the absence (-) or presence, respectively, of a p65 antibody (p65-CAb) on the DOC-activated
NF-KB forms. Lanes 5 and 6, two DOC-activated NF-KB forms from HeLa cytoplasmic (C) extracts or the nuclear (N) NF-KB complexes
induced after TNF-a treatment of HeLa cells, respectively. Lanes 7 to 9, effects of various antibodies on the TNF-a-induced nuclear NF-KB
complexes. The various NF-KB complexes are indicated (arrows). ns, nonspecific band. (C) Results of an SDS-10% PAGE analyzing the
coimmunoprecipitation of IKBa/MAD-3 with p65 antibodies (p65-NAb) using metabolically labeled (with [35S]methionine and [35S]cysteine)
HeLa extracts. Lanes 1 and 2, results of immunoprecipitating with p65-NAb alone or p65-NAb plus the competing peptide, respectively. The
inhibited bands are indicated (arrows). Lanes 3 and 4, results of a second immunoprecipitation with IKBaIMAD-3-Ab 9 alone or with
IKBax/MAD-3-Ab 9 plus the competing peptide, respectively, when the first immunoprecipitation is done with p65-NAb. Lanes S and 6, results
of a second immunoprecipitation with IKBaIMAD-3-Ab 9 alone or with IKBa/MAD-3-Ab 9 plus the competing peptide, respectively, when
the first immunoprecipitation is done with p65-NAb plus the competing peptide.
ylated in dephosphorylation buffer plus calf intestinal phos-
phatase (both from Boehringer Mannheim) in the presence
or absence of phosphatase inhibitors (NaF, Na3VO4, and
,B-glycerophosphate) and then subjected to Western blot
analysis.
Northern blots. HeLa S3 cells were stimulated with 10 ng
of TNF-a per ml for the periods indicated above. RNA
extraction and Northern (RNA) blot analysis were carried
out by a previously described procedure (1) using a radiola-
beled IKBa/MAD-3 probe.
RESULTS
Two forms of NF-KB are associated with IKBor/MAD-3 in
vivo. Cytoplasmic extracts generally contain little or no free
NF-KB. However, NF-KB is readily detectable when cyto-
plasmic extracts are treated with a disrupting agent like
sodium DOC (2). Interestingly, upon DOC treatment of
HeLa cytoplasmic extracts, two complexes were detected
by using an NF-KB major histocompatibility complex class I
enhancer probe (Fig. 1A, lanes 1 and 2). The complex
present in these extracts that approximately comigrates with
the DOC-activated complexes may represent a small amount
of free NF-KB. To determine whether the DOC-activated
complexes were associated with IKBoaIMAD-3, an immuno-
precipitation experiment was carried out by incubating cy-
toplasmic extracts with either a previously described IKBot/
MAD-3 antibody, IKBo3/MAD-3-Ab 9 (8), alone or IKBaL/
MAD-3-Ab 9 plus the peptide against which it was
generated. The immune complexes were then precipitated
with protein A-Sepharose and washed. IKBcIMAD-3-
NF-KB complexes were disrupted by the addition of DOC,
after which the supernatants were analyzed by a gel shift
assay. Both protein complexes were immunoprecipitated
with IKBd3IMAD-3-Ab 9 but not when the competing peptide
was present (Fig. 1A; compare lanes 3 and 4). These results
demonstrate that IKBa/MAD-3 is bound to at least two forms
of cytoplasmic NF-KB. Similar results were obtained with
the mouse pre-B-cell line 70Z/3, the human B-cell line Raji,
and human fibroblasts (data not shown).
To determine the identities of these two complexes, we
tested antibodies against the p50 and p65 subunits for
possible reactivity against these complexes (Fig. 1B). A
previously described p50 antibody (Ab 2) (31) did not super-
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shift either complex, most likely as a consequence of the
presence of DOC in the binding reaction (data not shown).
Using an alternate approach, we preincubated the extract
with p50-Ab 2 or with preimmune serum in addition to
protein A-Sepharose. The supernatant was then removed
and treated with DOC and then subjected to a gel shift
analysis (Fig. 1B). Interestingly, the faster-migrating com-
plex was almost completely depleted by p50-Ab 2 but not by
preimmune serum (Fig. 1B; compare lanes 1 and 2). The
more slowly migrating complex was not affected by p50-Ab
2 or by preimmune serum. However, an antibody against p65
(p65-CAb) supershifted both complexes (Fig. 1B, lane 4).
We then tested whether activation of NF-KB by an agent
such as TNF-a can lead to the appearance of both of these
complexes. Analysis of nuclear extracts from TNF-a-stimu-
lated HeLa cells showed the appearance of two complexes
with the same mobilities as the DOC-activated complexes
(Fig. 1B; compare lanes 5 and 6, upper and middle arrows).
In addition, the previously described p50 homodimers (31)
were also detected in these nuclear extracts (Fig. 1B, lanes 6
to 9, lower arrow). Furthermore, the middle and lower
complexes were supershifted with p50-Ab 2 while the middle
and upper complexes were supershifted with p65-CAb (Fig.
1B, lanes 7 and 8, respectively). None of the complexes were
affected by c-Rel antibodies, suggesting that c-Rel is unlikely
to be a component of these complexes (Fig. 1B, lane 9). The
c-Rel antibody has previously been shown to be capable of
supershifting c-Rel present in crude extracts (48).
ILl _
ns
FIG. 2. Treatment of cells with various inducers results in the
loss of IKBXIMAD-3 and concomitant appearance of nuclear NF-
KB. (A) A Western blot analysis of cytoplasmic extracts following
treatment of ceUls with different inducers. Equal numbers of cells
were either left untreated (-) or stimulated with the inducer(s)
indicated on the left. At the time points (in minutes) shown above
each panel, cytoplasmic and nuclear extracts were prepared. O',
samples processed immediately after addition of the inducer. Equiv-
alent amounts of cytoplasmic extracts were then analyzed by a
Western blot as indicated in Materials and Methods by using
IKBa/MAD-3 antibodies. IKBoa/MAD-3-Ab 9 was used for the
TNF-(, PMA, and PMA-PHA Western blots, while IKBa/MAD-3-
CAb was used following LPS and IL-la treatments. IKBeI/MAD-3
(arrow) and a nonspecific (ns) band are indicated. TNF-ot and PMA
treatments were carried out with HeLa cells, PMA-PHA treatment
was carried out with Jurkat cells, and LPS and IL-l(x treatments
were carried out with 70Z/3 cells. (B) Gel mobility shift analysis of
nuclear extracts following treatment of cells with different inducers.
Equal amounts of nuclear extract were analyzed by a gel shift assay
as described in Materials and Methods. Inducers are shown on the
left, and the time points (in minutes) are indicated above each panel.
The various forms of NF-KB which are induced following stimula-
tion are indicated (arrows).
We have generated an N-terminal p65 antiserum (p65-
NAb) which showed exclusive reactivity to the upper p65-
containing DOC-activated complex in the earlier bleeds.
Even in later bleeds, the antibody shows much higher affinity
for the upper complex than for the lower one (data not
shown). An immunoprecipitation with an early bleed of
p65-NAb using [35S]methionine- and [35S]cysteine-labeled
HeLa cell lysates (Fig. 1C) precipitated a protein of 65 kDa
(upper arrow) along with another protein, of 36 kDa (lower
arrow), both of which were inhibited by the peptide against
which p65-NAb was generated (Fig. 1C; compare lanes 1 and
2). The 36-kDa protein was shown to be IKBa/MAD-3 by
boiling the p65-NAb immunoprecipitates and performing a
second immunoprecipitation with IKB/MAD-3-Ab 9 (Fig.
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FIG. 3. In vivo phosphorylation of IKBa/MAD-3 following stim-
ulation with TNF-a. (A) A Western blot analysis demonstrating that
the modified form of IKBa/MAD-3 is phosphorylated. Equal
amounts of HeLa cytoplasmic extracts prepared 2.5 min after
TNF-a stimulation were either left untreated (lane 1) or treated with
calf intestinal phosphatase (CIP) alone (lane 2) or with CIP in the
presence (+) of phosphatase inhibitors (lane 3), as indicated at the
top. Samples were then analyzed by a Western blot with IKBa/
MAD-3-Ab 9. The modified and unmodified forms of IKBa/MAD-3
are indicated (arrows). (B) Immunoprecipitation of IKBa/MAD-3
after phosphate labeling of HeLa cells. HeLa cells were depleted of
phosphate, and then [3 P]H3PO4 was added. The samples in lanes 1
and 2 were left untreated, while the samples in lanes 3 and 4 were
stimulated for 2.5 min with TNF-oa. Cells were subsequently lysed,
IKBa/MAD-3 was immunoprecipitated with IKBa/MAD-3-Ab 9
alone (lanes 1 and 3) or IKBa/MAD-3-Ab 9 preincubated with the
peptide against which it was generated (lanes 2 and 4) and the
immunoprecipitate was analyzed by SDS-PAGE followed by auto-
radiography. IKBa/MAD-3 is indicated (arrow).
1C, lanes 3 to 6). No other specifically precipitated proteins
were detected. As expected, p65-CAb, which supershifts
both of the DOC complexes, also immunoprecipitated p50
along with p65 and IKBaIxMAD-3 (data not shown). These
results suggest that p65 homodimers might also be present in
cells and that the upper DOC-induced complex could be a
p65 homodimer. Taken together, our results demonstrate
that IKBa/IMAD-3 is associated in vivo with both a p50/65
heterodimer (NF-KB) and another complex that contains p65
but not p50 and is likely to be a p65 homodimer (also, see
Discussion).
Several stimuli, including TNF-a and IL-1c, cause the loss
of IKBaV/MAD-3 and the concomitant activation of NF-KB.
After establishing an in vivo interaction between NF-KB and
IKBa/MAD-3, we tested whether the levels of IKBa/MAD-3
were affected by treatment of cells with various agents that
are known to induce NF-KB DNA-binding activity. The
inflammatory cytokine TNF-ax was first tested on HeLa cells
which were previously shown to be responsive to this agent
(29). IKBax/MAD-3-Ab 9 readily detected a protein of 36 kDa
in the cytoplasm of these cells by a Western blot analysis
(data not shown). This protein was not detected when the
antiserum was first incubated with the peptide against which
IKBa/MAD-3-Ab 9 was raised, thereby establishing its iden-
tity as IKBa/MAD-3. HeLa cells were treated with TNF-a
and, subsequently, fractionated into cytoplasmic and nu-
clear extracts at various times after treatment. The cytoplas-
mic extracts from the different time points were then ana-
lyzed by a Western blot using IKB3c/MAD-3-Ab 9 (Fig. 2A).
Interestingly, the IKBa/MAD-3 signal completely disap-
peared after 15 min of treatment. A second band, which was
also inhibited by the IKBa/MAD-3-Ab 9 peptide, appeared
above IKBa/MAD-3 at the 2.5- and 5-min time points. This
band is likely to be a modified form of IKBa/MAD-3 (see
below). These results demonstrate that TNF-a stimulation of
HeLa cells causes the modification and eventual disappear-
ance of IKBa/MAD-3. Nuclear extracts from the TNF-ot-
stimulated cells were then analyzed by a gel shift assay using
1 2 3 4
the major histocompatibility complex class I NF-KB DNA-
binding site (Fig. 2B). Elevated levels of NF-KB were readily
detectable after 2.5 min of TNF-ot treatment. The two
complexes induced by TNF-ao are the same as the two
NF-KB complexes bound to IKBa/MAD-3 in uninduced
cytoplasmic extracts (see above; Fig. 1B). No detectable
nuclear form of IKB/AMAD-3 was noticed following its loss
from the cytoplasm, suggesting that its disappearance is not
a consequence of its translocation into the nucleus (data not
shown). Moreover, a C-terminal antibody against IKBa/
MAD-3 (IKBa/MAD-3-CAb) also demonstrated the loss of
the inhibitor from the cytoplasm, suggesting that the anti-
genic site for the N-terminal IKBBa/MAD-3-Ab 9 was not
simply being masked following stimulation with TNF-ot (data
not shown). We, therefore, surmise that the mechanism of
activation of NF-KB after stimulation of cells with TNF-a is
through the loss of IKBaIMAD-3, resulting in the transloca-
tion of free NF-KB into the nucleus.
We then tested whether other inducers of NF-KB can also
lead to the loss of IKBaIMAD-3. The tumor promoter and
activator of protein kinase C, PMA, is an established inducer
of NF-KB. HeLa cells were, therefore, treated with PMA,
and cytoplasmic extracts were tested for IKBa/MAD-3 as
described above (Fig. 2A). PMA stimulation also led to the
loss of IKBa/MAD-3 and to the appearance of NF-KB in
nuclear extracts (Fig. 2B). However, the rate of IKBa/
MAD-3 loss was slower than that seen after TNF-ot treat-
ment, and no modified form was noticed. Moreover, PMA
did not cause the complete loss of IKBaIMAD-3. We then
tested three other NF-KB inducers: PMA-PHA, which mim-
ics certain steps in T-cell activation, was tested on Jurkat T
cells (Fig. 2A), and the B-cell mitogen LPS and the inflam-
matory cytokine IL-la were tested on 70Z/3 pre-B cells (Fig.
2A). Once again, IKBa/MAD-3 disappeared after treatment
in all cases and the two p65-containing NF-KB complexes
concomitantly appeared in the nucleus (Fig. 2B, upper and
middle arrows in each panel). No modified form of IKB was
detected after PMA-PHA or LPS treatment, while a modi-
fied form was detected after IL-la treatment (Fig. 2A).
Interestingly, a small increase in the levels of p50 ho-
modimers was also detected, especially after PMA and LPS
treatments (Fig. 2B, lower arrow in each panel). Taken
together, these results suggest that the loss of IKBa/MAD-3
is a general mechanism for the activation of NF-KB.
To determine whether the modification of IKBaIMAD-3
was caused by phosphorylation, we tested HeLa cytoplas-
mic extracts made 2.5 min after TNF-a treatment which
contain both the modified and the unmodified forms of
IKBaA/MAD-3. Treatment of these extracts with calf intesti-
nal phosphatase followed by a Western blot analysis showed
that the modified form was converted to the unmodified form
(Fig. 3A; compare lanes 1 and 2). Furthermore, this effect of
calf intestinal phosphatase could be blocked if phosphatase
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FIG. 4. Both the loss of IKBot/MAD-3 and the activation of
NF-KB are inhibited in the presence of antioxidants. Jurkat cells
were stimulated with PMA-PHA with or without prior treatment
with the antioxidant PDTC (100 ,uM) as indicated, and then cyto-
plasmic and nuclear extracts were made. Western blotting was
performed on cytoplasmic extracts (A), while gel shift assays were
performed on nuclear extracts (B). IKBot/MAD-3 and NF-KB are
indicated (arrows). Similar experiments were carried out by pre-
treating 70Z/3 cells or HeLa cells with the antioxidant NAC (30
mM), then treating the cells with LPS or TNF-ot, respectively, and
analyzing them as described above.
inhibitors were included (Fig. 3A, lane 3). These results
suggest that the modified form of IKBa/IMAD-3 is the result
of phosphorylation. Using a different approach, we grew
HeLa cells in the absence of phosphate for 3 h, and then
radioactive 32P-labeled H3P04 was added. Subsequently, the
cells were stimulated with TNF-ac for 2.5 min, after which
the cells were lysed and IKBa/MAD-3 was immunoprecipi-
tated with IKBBa/MAD-3-Ab 9. Analysis of the immunopre-
cipitate by SDS-PAGE revealed a dramatic increase in
IKBadMAD-3 phosphorylation after TNF-a treatment (Fig.
3B; compare lanes 1 and 3). The identity of the phosphopro-
tein was confirmed by blocking the antiserum with the
peptide against which IKBa/MAD-3-Ab 9 was raised (Fig.
3B, lane 4). Moreover, these results also suggest that IKBa/
MAD-3 is not phosphorylated within the period of the
experiment when TNF-a is not present (Fig. 3B, lane 1). No
phosphorylated IKBot/MAD-3 was detected after 30 min of
TNF-ao treatment, a result consistent with our previous
observations on the loss of IKBa3/MAD-3 following stimula-
tion (data not shown).
Both the loss of IKcBot/MAD-3 and the activation of NF-KB
are inhibited in the presence of antioxidants. Recent studies
have shown that oxidizing agents like hydrogen peroxide
(H202) can lead to the activation of NF-K<B (42). The
oxidizing properties of H202 are due to its breakdown into
ROI inside cells. Most interestingly, it has been reported that
antioxidants can block the activation of NF-KcB by not only
H202 but also other, seemingly unrelated inducers like
TNF-ao, PMA-PHA, and LPS (41, 42, 45). These results
suggest that different signaling pathways could involve the
release of ROI as a signaling moiety. However, no conclu-
sive evidence regarding the stage at which the blockage of
the activation of NF-KcB occurs has been generated. In light
of these observations, we tested whether the loss of IKBa/
MAD-3 could take place in the presence of antioxidants. We
therefore tested the effects of the antioxidants PDTC and
NAC on the abilities of different inducers to cause the loss of
IKBa/MAD-3 (Fig. 4). A Western blot analysis showed that
the ability of PMA-PHA to cause the loss of IKBaIMAD-3 in
Jurkat T cells was almost completely abolished in the
presence of PDTC (Fig. 4A). A gel shift analysis showed that
PDTC also inhibited the activation of NF-KB by PMA-PHA
(Fig. 4B). Moreover, LPS could not cause the complete loss
of IKBa/MAD-3 when 70Z/3 cells were pretreated with NAC
(Fig. 4A). A gel shift analysis also showed that NF-KB was
only partially activated by LPS stimulation in the presence
of NAC (Fig. 4B). Similar results were obtained when HeLa
cells were treated with TNF-ao in the presence of NAC (Fig.
4). PDTC or NAC had no effect on the viability of cells
during the course of these treatments. We have also found
that the treatment of 70Z/3 cells with H202 resulted in a
gradual decrease in IKBa/MAD-3 levels and a corresponding
translocation of NF-KB into the nucleus (data not shown).
Interestingly, PDTC seemed more effective than NAC in
preventing the loss of IBad/MAD-3 caused by PMA-PHA
while NAC was more effective than PDTC after TNF-a and
LPS stimulation (data not shown). These results could be
due to the difference in the abilities of these two antioxidants
to penetrate different cell types or their abilities to neutralize
ROI once inside the cells. In any case, our results demon-
strate that both the activation of NF-KB and the loss of
IKBax/MAD-3 are inhibited in the presence of antioxidants.
They also demonstrate that the loss of IKBaL is required for
NF-KB activation.
IKcBc/MAD-3 is rapidly resynthesized after loss, indicating
an autoregulatory mechanism. The continued absence of
IKBa/MAD-3 after the stimulation of cells represents a
situation in which newly synthesized NF-KB may be rapidly
translocated into the nucleus. This would lead to a long-term
transcriptional activation of NF-iB-responsive genes and to
possible deleterious effects on cells. However, renewed
synthesis of IKBaIMAD-3 would make this response tran-
sient by binding to the newly synthesized NF-KB. We
therefore tested whether IKBaIMAD-3 is resynthesized after
its loss (Fig. 5A). A Western blot analysis revealed that,
after only 1 h of TNF-ac treatment, the levels of IKBaIMAD-3
returned to approximately half the original level (Fig. 5A;
compare lanes 1 and 3). This response was blocked by
cycloheximide, demonstrating that new synthesis is respon-
sible for the reappearance of IKBa/MAD-3 (Fig. 5A, lane 4).
Cycloheximide alone resulted in only a small decrease in
IKBX/MAD-3 levels (data not shown). Similar results were
obtained after stimulation of cells with IL-la, PMA, PMA-
PHA, and LPS (data not shown). Interestingly, a small
amount of the newly synthesized IKBa/MAD-3 was modified
(Fig. 5A, lane 3), indicating that a TNF-ac-induced kinase
remains partially active for at least 1 h after treatment.
Additional proof for renewed synthesis of IKBa/MAD-3 was
obtained by Northern blot analysis (Fig. 5B). TNF-at treat-
ment strongly increased the levels of IKBa/MAD-3 mRNA
(Fig. 5B; compare lanes 1 and 2), and these levels remained
elevated for at least 2 h (Fig. 5B, lanes 2 to 4). On the basis
of these results, we propose that the loss and resynthesis of
IKBa/MAD-3 is part of an autoregulatory mechanism that
ensures that NF-KB activation is essentially transient. It also
raises the possibility that NF-KB regulates the IKBBaIMAD-3
promoter in a manner similar to the regulation of the NF-KB
p50/105 promoter (49).
DISCUSSION
Loss of IKBci4MAD-3: a general mechanism for the activa-
tion of NF-KB. Numerous studies have shown that the
transcription factor NF-KB is an important regulator of genes
involved in a variety of cellular activities. These studies have
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FIG. 5. IKBa/MAD-3 loss is transient. (A) Western blot analysis
of HeLa cells after stimulation with TNF-a. Equal numbers of cells
were either left untreated (-) (lane 1) or treated with TNF-a for the
indicated times (in minutes). The sample in lane 4 was incubated for
30 min with cycloheximide (Cyclo) prior to TNF-a treatment.
Cytoplasmic extracts were then prepared and analyzed by Western
blot using IKBaz/MAD-3-Ab 9. IKBa/MAD-3 (arrow) and a nonspe-
cific (ns) band are indicated. (B) Northern blot analysis of HeLa
cells after stimulation with TNF-a. Equal numbers of cells were
either left untreated (-) or stimulated with TNF-a for the indicated
times (lanes 2 to 4). Poly(A) RNA was isolated, and Northern blot
analysis was performed as described in Materials and Methods, by
using a probe specific for the IKBa/MAD-3 mRNA. The same blot,
stripped and reprobed with a probe specific for glyceraldehyde
3-phosphate dehydrogenase (GAPDH), is shown at the bottom.
typically involved the stimulation of cells with agents that
can lead to the appearance of NF-KB in the nucleus or by in
vivo transactivation assays using reporter plasmids contain-
ing NF-KB-responsive sites derived from the promoter-
enhancer regions of a variety of different genes. However,
there is no information available on the general mechanism
of NF-KB activation. We have previously reported that the
presence of IKBaIMAD-3 is sufficient to retain both the p5O
and the p65 subunits of NF-KB in the cytoplasm while the
absence of IKBaIMAD-3 allows these subunits to be trans-
ported into the nucleus (8). These results prompted us to
investigate the status of IKBB/MAD-3 after stimulation of
cells with different NF-KB inducers. Here, we demonstrate
that stimulation of cells with five different inducers of NF-KB
leads to the loss of IKBa./MAD-3 and to the concomitant
appearance of NF-KB in the nucleus (Fig. 2). The kinetics of
this process varied for different inducers; for example, in
pre-B cells IL-la could cause the complete loss of IKBa/
MAD-3 in only 5 min while approximately 30 min was
required for this process by LPS. The difference in kinetics
of IKBaA/MAD-3 loss among different inducers could be at
any number of different steps which precede the loss of
IKBa/MAD-3. In any case, the kinetics of IKBa/MAD-3 loss
closely parallel the nuclear appearance of NF-KB, indicating
that the rate-limiting step in the activation of NF-KB is the
loss of IKBa/MAD-3. It would be interesting to see whether
other IKB forms like Bcl-3 and p105 are also targeted by the
various inducers of NF-KB.
Interestingly, we found that two major forms of NF-KB are
associated with IKBaz/MAD-3 and that both forms were
liberated in an active DNA-binding form following stimula-
tion of cells with NF-KB inducers (Fig. 1B). We have found
that the faster-migrating form is p50/65 NF-KB while the
more slowly migrating form contains p65 but not p50 and is
likely to be a p65 homodimer (Fig. 1B). UV cross-linking of
these complexes to a radiolabeled DNA fragment has con-
firmed these results (7a). Since the p50 and p65 subunits of
NF-KB have different DNA-binding site specificities as well
as different transcriptional activation properties (32, 35, 40),
it is possible that these two complexes provide diverse
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functions in the regulation of NF-KB-responsive genes. In
general, only p50/65 NF-KB has been shown to be activated
in different cell lines after stimulation with different agents,
although several KB-binding complexes have been shown to
be activated after PMA-PHA treatment of Jurkat T cells (7).
However, our results indicate that two major idB-binding
complexes are activated after stimulation of cells with a
variety of different agents (Fig. 2B). The more slowly migrat-
ing p65-containing form might have previously gone unde-
tected because of differences in the DNA-binding sites used
or because of binding reaction conditions that were different
from those that were used here. For the same reason, it is
possible that we did not detect other proteins bound to
IKBa/MAD-3. This might also explain why c-Rel, which has
previously been shown to be associated with IKBc/MAD-3
(38), was not detected in nuclear extracts of stimulated cells
(Fig. 1B). On the other hand, only a very small proportion of
c-Rel may actually be associated with IKBa/MAD-3. A slight
increase in p50 homodimer DNA binding was also noticed
after stimulation of cells (Fig. 2B). This could be due to the
association of a small amount of p50 homodimers with
IKBa/MAD-3, consistent with previous observations on the
abilities of these proteins to associate in vitro (8).
Here, we have provided the first in vivo evidence that
IKBaIMAD-3 is phosphorylated after stimulation of cells
with NF-KB inducers (Fig. 3). These results may provide
important insights into the first steps involved in the mech-
anism of NF-KB activation. However, at present it is unclear
what the exact role of IKBBa/MAD-3 phosphorylation is in its
release from NF-KB. Most likely and consistent with the
results of previous in vitro experiments, phosphorylation of
IKBa/MAD-3 dissociates it from NF-KB (20, 30). This would
be followed by the translocation of free NF-KB into the
nucleus while the unbound IKBaIMAD-3 becomes suscepti-
ble to proteolysis because of the exposure of a previously
masked proteolytic cleavage site. However, it is also possi-
ble that phosphorylation makes IKBa/MAD-3 susceptible to
proteolysis but does not cause its release from NF-KB. In
this situation, it would actually be the proteolysis of IKBa/
MAD-3 which would be involved in the release of NF-KB,
even though phosphorylation would be a prerequisite for it
to occur.
During TNF-a stimulation, unmodified IKBa/MAD-3 first
seemed to be phosphorylated and then was lost, indicating
that the phosphoprotein is extremely short-lived (Fig. 2A).
Our results indicate that, although phosphorylation of IKBa/
MAD-3 is evident in the case of stimulation of cells with
fast-acting inducers like TNF-cx and IL-la, the slowly acting





























FIG. 6. A mechanism for the autoregulation of NF-KB (see text for details).
form. Since the phosphoprotein is extremely labile, it is
possible that for slowly acting inducers the rate of conver-
sion of the unmodified IKBaIMAD-3 to the modified form is
slower than the rate of disappearance of the modified form
by proteolysis. In this instance, phosphorylated IKBa/
MAD-3 would never exist in a concentration large enough to
be detectable at any given time. Therefore, the inability to
detect phosphorylated IKBa/MAD-3 by stimulation of cells
with inducers like PMA, PMA-PHA, and LPS does not
indicate that phosphorylation is not involved.
Implications of IKBav/MAD-3 phosphorylation for under-
standing cytokine signal transduction pathways. Recent stud-
ies have identified a pathway for TNF-a signaling which is
distinct from the protein kinase C pathway and involves the
production of ceramide by a sphingomyelinase (15, 43).
Sphingomyelinase activation has been linked to the produc-
tion of DAG by a phosphatidylcholine-specific phospho-
lipase C. Interestingly, a ceramide-activated protein kinase
which appears to phosphorylate a minimum sequence of
X-Ser/Thr-Pro-X, distinct from the consensus substrate se-
quences of other serine/threonine protein kinases has been
recently identified (15, 34). Intriguingly, several such pro-
line-containing sequences can be found in the ankyrin repeat
domains and in the C-terminal end of the predicted IKBot/
MAD-3 amino acid sequence (23).
The abilities of the cytokines TNF-ax and IL-la to influ-
ence numerous biological processes are largely dependent
on their abilities to regulate gene expression. However, the
failure to identify physiologically relevant substrates impor-
tant for the regulation of gene expression has prevented an
understanding of the signaling mechanisms of these cyto-
kines. We believe that IKBa/MAD-3 represents an important
functional target for these cytokines. Since NF-KB is a
known regulator of a number of immune and inflammation
response genes, its activation through the phosphorylation
of IKBa/MAD-3 provides important insights into the mech-
anisms of cytokine signal transduction.
Both the loss of IKBzA/MAD-3 and the activation of NF-KB
are inhibited in the presence of antioxidants. Considerable
attention has been focused recently on the ability of antiox-
idants to block the activation of NF-KB by virtually all
inducers tested (41, 42, 45). These studies have indicated
that ROI may be a component of several signal transduction
pathways since the presence of antioxidants like PDTC and
NAC can block these pathways. Here, we have shown that
the effect of these agents manifests itself in the prevention of
IKBa/MAD-3 loss caused by NF-KB inducers (Fig. 4). The
abilities of three different inducers, PMA-PHA, LPS, and
TNF-a, to cause the loss of IKBa/MAD-3 were partially or
completely blocked in the presence of either NAC or PDTC.
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The inability to cause the complete loss of IKBa/MAD-3 in
the presence of antioxidants was clearly reflected in the
partial or complete inhibition of the activation of NF-KB
after stimulation with these agents (Fig. 4). Interestingly, we
have noticed that inducers which cause a relatively slow loss
of IKBa/MAD-3 (PMA-PHA and LPS) were almost com-
pletely blocked by antioxidants while those which cause a
rapid loss of IKBaILMAD-3 were either partially affected, as
in the case of TNF-a (Fig. 4), or not affected at all, as in the
case of IL-la (data not shown). It is possible that PMA-PHA
and LPS lead to the slow release of low concentrations of
ROI, which can be effectively neutralized by antioxidants,
while TNF-a and IL-la cause the rapid release of large
amounts of ROI, which are inefficiently neutralized by
antioxidants under the experimental conditions used. The
exact role of ROI in signal tranduction is still unclear,
although on the basis of our results for the in vivo phos-
phorylation of IKBa/MAD-3, we propose that the mecha-
nism could involve the activation of a kinase.
The resynthesis of IKBcv/MAD-3 following loss provides
evidence for an autoregulatory mechanism. The results pre-
sented here demonstrate that the loss of IKBa/MAD-3 fol-
lowing treatment of cells with NF-KB inducers is essentially
transient (Fig. 5). In the case of TNF-a, a significant amount
of IKBa/MAD-3 has already been resynthesized after 1 h of
treatment (Fig. 5A). Northern blot analysis of IKBaIMAD-3
after TNF-a treatment showed that the new synthesis of
IKBa/MAD-3 protein is likely due to the transcriptional
induction of the IKBa/MAD-3 mRNA (Fig. 5B). Similar
results were also obtained with other inducers of NF-KB
used in this study (data not shown), raising the possibility
that NF-KB is itself involved in the transcriptional induction
of IKBa/MAD-3 mRNA. However, formal proof for this
must await the identification of functional NF-KB-binding
sites in the IKBa promoter. Since nuclear NF-KB has a short
half-life, it would eventually get depleted if new NF-KB were
not transported from the cytoplasm (26). The resynthesis of
IKBa/lMAD-3 would ensure that the newly synthesized
NF-KB is, in fact, sequestered in the cytoplasm. This could
be the basis for an autoregulatory mechanism which would
ensure that the induction of NF-KdB is transient and that the
cell returns to an uninduced state within a relatively short
period. This mechanism would ensure that NF-KB-regulated
genes are only transiently induced and would therefore avoid
any deleterious effects due to the continued activation of
these NF-KB-responsive genes.
On the basis of this study and previous results, we propose
a model (Fig. 6) in which the engagement of a specific cell
surface receptor leads to the activation of a kinase by a
pathway that may involve the production of ROI (step 1 in
Fig. 6). The activated kinase phosphorylates IKBa/MAD-3,
leading to its dissociation from NF-KB (step 2). The free
NF-KB complex is then translocated into the nucleus (step 3)
because of the exposure of its nuclear localization sequence
previously masked by IKBct/MAD-3 (8). Nuclear NF-KB can
transcriptionally activate various immune and inflammation
response genes as well as those encoding IKB3a/NAD-3 and
p50/105 (step 4). These mRNA species then give rise to
functional proteins which reestablish the inactive cytoplas-
mic NF-KB complexes (step 5). The p50 protein is derived
from the cleavage of the p105 precursor (21, 31), while the
p65 protein is synthesized from a constitutively produced
mRNA (29a). This model proposes a negative-feedback
mechanism which ensures an essentially transient NF-KB
activation following cell stimulation.
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ADDENDUM IN PROOF
Two recent articles (K. Brown, S. Park, T. Kanno, G.
Franzoso, and U. Siebenlist, Proc. Natl. Acad. Sci. USA
90:2532-2536, 1993; S.-C. Sun, P. A. Ganchi, D. W. Ballard,
and W. C. Greene, Science 259:1912-1915, 1993) also show
the loss of IKBa following treatment of cells with NF-KB
inducers as well as the autoregulation of NF-KB through
renewed synthesis of IKBa.
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